Author: admin

Ulcerative Colitis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ulcerative Colitis pipeline constitutes 70+ key companies continuously working towards developing 75+ Ulcerative Colitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Ulcerative Colitis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.

 

The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Ulcerative Colitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years.

  • Ulcerative Colitis companies working in the treatment market are NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others, are developing therapies for the Ulcerative Colitis treatment

  • Emerging Ulcerative Colitis therapies in the different phases of clinical trials are- MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.

  • In July 2025, Abivax SA has reported favorable topline results from its Phase 3 induction trials, ABTECT-1 (Study 105) and ABTECT-2 (Study 106), assessing obefazimod (ABX464) in adult patients with moderate to severe ulcerative colitis (UC) over an 8-week treatment period.

  • In February 2025, Johnson & Johnson’s (J&J) fully subcutaneous formulation of Tremfya (guselkumab) has delivered a second positive outcome in ulcerative colitis (UC), with 27.6% of participants achieving clinical remission in a Phase III trial. The randomized, double-blind Phase III Astro trial (NCT05528510) evaluated the subcutaneous injectable form of Tremfya for both induction and maintenance treatment in 418 adults with moderate to severe UC, an inflammatory bowel disease (IBD), who had previously shown an inadequate response to standard therapies.

  • In February 2025, Iterative Health, a healthcare technology and services company focused on enhancing gastrointestinal care in collaboration with physicians, is set to present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, from February 19–22, 2025. The presentations will highlight the exceptional performance of the company’s AI-enabled Endoscopic Score (AI-ES) and its extended version (AI-ESe) in delivering standardized, reproducible assessments of disease severity and treatment response in ulcerative colitis (UC). These findings were developed in partnership with Eli Lilly and Company and leading academic experts.

  • In February 2025, Teva and Sanofi have released new findings from the Phase IIb RELIEVE UCCD trial assessing duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody that targets TL1A, for treating moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The updated data were presented at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO) held in Berlin, Germany.

 

Ulcerative Colitis Overview

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by inflammation and ulcers in the lining of the colon and rectum. It is believed to be caused by an abnormal immune response in which the body’s immune system mistakenly attacks healthy tissues in the gastrointestinal tract.

 

Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight

 

Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:

  • PRA023: Prometheus Biosciences

  • OSE-127: OSE Immunotherapeutics

  • Brazikumab: AstraZeneca

  • MORF-057: Morphic Therapeutic

  • Risankizumab: AbbVie

  • Cobitolimod: InDex Pharmaceuticals

  • Etrasimod: Pfizer

  • PL8177: Palatin Technologies, Inc

  • Mirikizumab: Eli Lilly and Company

  • Guselkumab: Janssen Research & Development, LLC

  • Efavaleukin alfa: Amgen

  • NX-13: Landos Biopharma Inc.

  • Remestemcel-L: Mesoblast, Inc.

  • Ozanimod: Bristol-Myers Squibb

  • ABX464: Abivax S.A.

  • VTX002: Oppilan Pharma Ltd

  • AJM300: EA Pharma Co., Ltd.

  • PRA023 IV: Prometheus Biosciences, Inc.

  • SAR443122: Sanofi

  • GLPG3970: Galapagos NV

  • Ozanimod: Celgene

 

Ulcerative Colitis Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Ulcerative Colitis Molecule Type

Ulcerative Colitis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Ulcerative Colitis Pipeline Therapeutics Assessment

  • Ulcerative Colitis Assessment by Product Type

  • Ulcerative Colitis By Stage and Product Type

  • Ulcerative Colitis Assessment by Route of Administration

  • Ulcerative Colitis By Stage and Route of Administration

  • Ulcerative Colitis Assessment by Molecule Type

  • Ulcerative Colitis by Stage and Molecule Type

 

DelveInsight’s Ulcerative Colitis Report covers around 75+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the emerging Ulcerative Colitis therapies

 

Some of the key companies in the Ulcerative Colitis Therapeutics Market include:

Key companies developing therapies for Ulcerative Colitis are – Merck & Co., Inc.,, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Eli Lilly and Company, AbbVie Inc. (Allergan, Inc.), Bausch Health Companies Inc., Johnson and Johnson, Novartis AG, Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., and others.

 

Ulcerative Colitis Pipeline Analysis:

The Ulcerative Colitis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.

  • Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Ulcerative Colitis drugs and therapies

 

Ulcerative Colitis Pipeline Market Drivers

  • Increasing awareness and R&D investment, emergence of large number of novel pipeline molecules with great market potential are some of the important factors that are fueling the Ulcerative Colitis Market.

 

Ulcerative Colitis Pipeline Market Barriers

  • However, side effects associated with the treatment, high cost treatment and other factors are creating obstacles in the Ulcerative Colitis Market growth.

 

Scope of Ulcerative Colitis Pipeline Drug Insight

  • Coverage: Global

  • Key Ulcerative Colitis Companies: NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others

  • Key Ulcerative Colitis Therapies: MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others

  • Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies

  • Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers

 

Request for Sample PDF Report for Ulcerative Colitis Pipeline Assessment and clinical trials

 

Table of Contents

1. Ulcerative Colitis Report Introduction

2. Ulcerative Colitis Executive Summary

3. Ulcerative Colitis Overview

4. Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment

5. Ulcerative Colitis Pipeline Therapeutics

6. Ulcerative Colitis Late Stage Products (Phase II/III)

7. Ulcerative Colitis Mid Stage Products (Phase II)

8. Ulcerative Colitis Early Stage Products (Phase I)

9. Ulcerative Colitis Preclinical Stage Products

10. Ulcerative Colitis Therapeutics Assessment

11. Ulcerative Colitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ulcerative Colitis Key Companies

14. Ulcerative Colitis Key Products

15. Ulcerative Colitis Unmet Needs

16 . Ulcerative Colitis Market Drivers and Barriers

17. Ulcerative Colitis Future Perspectives and Conclusion

18. Ulcerative Colitis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences

Whispering Brook Financial Launches Wealth Map Radio, Helping Individuals Navigate the Nuances of Retirement Planning

Hosted by Steve Eckroth, the new radio show tackles real-world retirement concerns with practical strategies and accessible insights.

Newtown Square, PA – July 31, 2025 – Whispering Brook Financial, a firm known for its personalized, tax-conscious retirement planning strategies, has launched its new weekly radio program, Wealth Map Radio. Hosted by Steve Eckroth, CEO and Founder, the show airs every Saturday at 10 am on 990AM The Answer, a Philadelphia-based radio station. Episodes are also available on Spotify, Amazon Music, and Apple Podcasts.

Wealth Map Radio aims to demystify complex financial topics and equip listeners with timely and actionable information on the often-overlooked components of retirement and long-term income planning. Drawing on more than two decades in the finance industry, Mr. Eckroth discusses topics such as social security timing, asset-based long-term care, tax management, inflation considerations, and how to build a sustainable income plan in retirement.

“Most people only pay attention to the big picture – how much they’ve saved or when they can stop working. But it’s often the smaller, strategic decisions that determine whether your retirement income lasts or falls short,” said Mr. Eckroth. “Wealth Map Radio is about unpacking those finer points in a clear, accessible way.”

The radio show maintains a consistent focus on long-term retirement planning and sustainable outcomes. Each episode is structured to address one key aspect of financial preparedness, offering a topic-driven format and education perspectives grounded in Mr. Eckroth’s experience working with clients navigating real-world scenarios.

Wealth Map Radio is an extension of Whispering Brook Financial’s personalized retirement planning process and its proprietary Compass Report, a strategic outline designed to help individuals map out a path to retirement that focuses on tax efficiency, income planning, and risk reduction. This report outlines general strategies for organizing taxable and tax-deferred assets in a way that may help support long-term income stability in retirement.

By translating these retirement principles into a radio format, Wealth Map Radio seeks to promote broader awareness of issues that can have long-term effects on retirement success. The show bridges public education and in-depth advisory work, providing listeners access to foundational financial knowledge that empowers them to ask better questions and make more informed decisions.

Wealth Map Radio is updated weekly and available to stream or download through major platforms. Each new episode is added every Saturday morning, and listeners can also access the full archive of past episodes by visiting www.wealthmapradio.com.

About Whispering Brook Financial

Whispering Brook Financial is an independent financial services firm specializing in tax-efficient and holistic retirement strategies. The firm provides individualized guidance through its Compass Report, helping clients identify opportunities to increase retirement income, mitigate common financial risks, and pursue a more fulfilling retirement.

Socials: LinkedIn, Facebook

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Whispering Brook Financial
Email: Send Email
Phone: (484) 423-3434
Country: United States
Website: http://www.wealthmapradio.com/

WINK Streaming Announces Graceful End of Life Timeline for WINK Encoder and WINK Wall

WINK Streaming Announces Graceful End of Life Timeline for WINK Encoder and WINK Wall

Wink Logo
WINK Streaming announces the End of Life timeline for WINK Encoder and WINK Wall with 7 years of free security updates

MIAMI, FL – WINK Streaming today announced the End of Life timeline for WINK Encoder and WINK Wall products, with an unprecedented commitment to provide free security updates through December 31, 2031. This announcement reflects the company’s evolution toward cloud-native solutions while maintaining extraordinary support for existing customers.

Key Dates:

• October 31, 2026: End of Life – Final feature updates and bug fixes

• December 31, 2031: End of Security Support – Conclusion of security patch availability

• 7 Years: Industry-leading duration of free security updates for all customers

A Celebration of Success

After 16 years of powering video infrastructure for thousands of organizations worldwide, WINK Encoder has been a cornerstone of professional video delivery. WINK Wall has similarly transformed command centers and control rooms across government agencies, transportation departments, and enterprises.

“This isn’t goodbye – it’s an evolution,” said David Brown, Director of Marketing at WINK Streaming. “We’re incredibly proud of what these products have achieved and even more excited about guiding our customers to our next-generation cloud solutions that offer enhanced capabilities, easier management, and lower total cost of ownership.”

Unmatched Customer Commitment

WINK Streaming’s promise of 7 years of free security updates sets a new industry standard for product support. All existing customers will continue to receive:

• Full feature support and bug fixes through October 31, 2026

• Critical security patches through December 31, 2031

• Dedicated migration assistance to modern WINK solutions

Looking Forward Together

“We want to thank every customer who has trusted WINK Encoder and WINK Wall over the years,” Brown continued. “Your feedback and partnership have shaped these products into industry standards. Now, we’re excited to bring you along on the next chapter with solutions that are more powerful, more flexible, and easier to deploy than ever before.”

Customer Support

WINK Streaming has established a dedicated transition team to assist customers with migration planning. Organizations can contact their account representatives or visit wink.co/contact-us to discuss migration options and take advantage of special transition offers.

About WINK Streaming

WINK Streaming provides enterprise-grade video distribution solutions for government agencies, educational institutions, and large enterprises. With a focus on security, reliability, and innovation, WINK Streaming enables organizations to maximize their video infrastructure investments while embracing cloud-native technologies.

Media Contact
Company Name: WINK Streaming
Contact Person: David Brown
Email: Send Email
Country: United States
Website: https://www.wink.co

Lujy Tech Launches Remoteo, An Innovative App That Transforms Smartphones Into Universal TV Remotes

Losing a TV remote is a very common yet annoying problem. Relaxing in front of the TV is one of modern society’s guilty pleasures. This is why losing the remote control—whether it is under the couch cushions, being chewed on by a dog, or hidden by a toddler—can be frustrating enough to provoke shouting. In a world where smart TVs dominate peoples homes, the dependency on remote controls has only increased—and so has the frequency of misplacing them.

Lujy Tech, LLC, a premier software company that specializes in delivering quality lifestyle, financial, and utility apps, offers a new solution with the launch of its latest application on Android and iOS platforms. Remoteo – Universal TV Remote is a brand-new app designed to solve remote control problems. Remoteo is compatible not only with a single TV brand but also with all major TV brands such as Samsung, Sony, LG, Amazon Fire Stick, Roku TV, and Hisense. Remoteo solves the common issue of misplaced TV remotes by transforming any smartphone into a universal remote, always accessible and ready to use. Recognized as one of the top universal remote apps for smart TVs, Remoteo is ideal for households managing various devices and brands.

This app supports Lujy Tech’s goal of providing simple and affordable utility applications. It enhances productivity by removing the hassle and irritation caused by day-to-day problems. The powerful features of Remoteo – Universal TV Remote go beyond the capabilities of traditional physical remotes. Remoteo offers more than basic functions like channel switching or volume control. It enables direct casting of videos, photos, and music from a smartphone to a TV—without requiring additional apps. From showcasing vacation snapshots to presenting a quick slideshow before a meeting, everything is accessible with a single tap.

The layout is simple and intuitive, with features placed exactly where expected. No need to scroll endlessly through menus or guess the meaning of icons. Even users with minimal tech experience can navigate it effortlessly.

Remoteo stands out from typical remote apps that only support a single brand. It streamlines control for multiple TVs across different rooms—whether it’s Samsung, LG, Fire Stick, or others. No app-switching or complicated setup required—just launch and control.

Beyond changing channels or adjusting volume, Remoteo unifies all smart TVs in one place. Managing devices in the living room, bedroom, or kitchen becomes seamless, with no need to juggle apps or face pairing issues. Everything operates from one app, directly on a smartphone.

Simplifies control of the entire entertainment setup. Functionality goes beyond volume and channels, offering built-in casting and screen mirroring to instantly share photos, videos, or music from a smartphone to any compatible device, regardless of brand. Supports voice commands and continually improves through regular updates. With each new smart TV model or software version, Remoteo remains up to date, eliminating concerns about compatibility or obsolescence.

With more homes using connected devices, having one app that just works across everything makes a big difference. Remoteo fits right in—it’s reliable, simple to use, and built to keep up with how people actually watch TV today. One app. All screens. Complete control. The app is now available globally on the Apple App Store (iOS) and Google Play Store (Android).

Media Contact
Company Name: Remoteo – Universal TV Remote
Contact Person: Lujy Tech LLC
Email: Send Email
Country: United States
Website: https://www.remoteo.app

Goody Garage Doors Expands to Tucson, Bringing Arizona’s Top-Rated Service to Southern Arizona

Goody Garage Doors, Arizona’s highest rated garage door repair and installation company, is excited to announce the opening of its newest location at 7620 N Hartman Ln, Suite 106, Tucson, AZ 85743. This expansion marks a significant milestone in Goody Garage Doors’ mission to deliver exceptional garage door services to homeowners and businesses across the state.

With a proven reputation for fast, reliable service and unmatched customer satisfaction, Goody Garage Doors has earned thousands of five-star reviews throughout Arizona. The new Tucson location will provide the same trusted repair, installation, and maintenance services that have made Goody Garage Doors the preferred choice for families and businesses alike.

“We’re thrilled to become part of the Tucson community,” said Travis Trentham, Owner of Goody Garage Doors. “Our team is committed to bringing our family-first culture and top-tier craftsmanship to every customer in Southern Arizona. Whether it’s an emergency repair or a brand-new installation, our promise is simple: quality you can trust, every time.”

The Tucson branch will offer:

– 24/7 emergency garage door repair

– Professional installation of premium garage doors and openers

– Comprehensive maintenance and tune-ups

– Free estimates and industry- leading warranties

Goody Garage Doors invites Tucson residents to experience why they are Arizona’s most recommended garage door company.

About Goody Garage Doors

Goody Garage Doors is a locally owned and operated company providing expert garage door repair and installation services across Arizona. Known for integrity, excellence, and family-first values, Goody Garage Doors delivers quality products, superior workmanship, and exceptional customer care. For more information, visit www.goodygaragedoors.com or call (520) 314-1470.

Media Contact
Company Name: Goody Garage Doors
Contact Person: Travis Trentham, Owner
Email: Send Email
Phone: (520) 314-1470
City: Tucson
State: Arizona
Country: United States
Website: https://goodygaragedoors.com/

SkipClass Is Leading the Shift From Traditional Education to AI-Driven Upskilling

SkipClass.ai, an AI-powered learning platform built to help ambitious young professionals and learners master high-leverage skills like sales, coding, finance and others, officially launched out of stealth. Founded by Raphael Assor, a former military service member and a self-taught software engineer, and Jared Zelman, a recent USC graduate, SkipClass is leading a new wave of AI learning that emphasizes active self-learning, simulation-based experiences, and skill-building rooted in real-world performance, not passive video watching.

Designed for the modern, self-driven learner, SkipClass blends proprietary AI with exclusive insights from some of the world’s most respected thinkers and leaders. These include simulated AI professors modeled after exclusive content from experts like Robin Sharma, Richard Dawkins, Jimmy Carr, and George Church, capturing not just what they know, but how they think and teach.

“We help young professionals master high-level skills through real-world simulations, instant feedback, and personalized coaching from AI versions of the world’s top thinkers and operators,” said Assor.

SkipClass was originally launched in 2024 as an AI research lab focused on performance-based learning design. The team quickly realized that today’s learners weren’t looking for another educational subscription; they wanted on-demand mastery, optimized for upskilling, execution, and long-term retention.

“Modern education is still too passive,” said Zelman. “We’re building a new operating system for learning, something designed for speed, relevance, and mastery. Whatever your situation may be, SkipClass is for people who want to skip the fluff and level up fast.”

Unlike traditional edtech platforms that serve enterprises or institutions, SkipClass.ai is a consumer-first product. It’s designed for ambitious professionals and young learners looking to skip outdated methods and go straight to mastery on their own time, at their own pace.

Rather than relying on videos, lectures, or flashcards, SkipClass puts learners into immersive learning environments driven by AI professors. These experiences simulate real-world challenges, from negotiating deals to debugging code, paired with instant, contextual feedback. It’s education built for performance, not just consumption.

As SkipClass exits stealth mode, the company plans to expand its roster of AI mentors, deepen its personalization engine, and strengthen its university collaborations—all while continuing to build a new standard for AI-powered skill building.

Media Contact
Company Name: SkipClass
Contact Person: Jared Zelman
Email: Send Email
Country: United States
Website: https://skipclass.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SkipClass Is Leading the Shift From Traditional Education to AI-Driven Upskilling

HER2-Negative Metastatic Breast Cancer Pipeline Insight, 2025: Immunotherapy and ADCs Drive Innovation Across HR+ and TNBC Subtypes | DelveInsight

“HER2-Negative Metastatic Breast Cancer Pipeline”
The HER2-negative metastatic breast cancer (MBC) landscape is rapidly evolving, with over 50 candidates in clinical development across hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) subtypes. Novel approaches—including antibody-drug conjugates (ADCs), immune checkpoint inhibitors, AKT inhibitors, PARP inhibitors, and TROP2-targeted therapies—are at the forefront of innovation as developers pursue more durable, biomarker-driven treatment strategies.

The HER2-negative metastatic breast cancer (MBC) landscape is rapidly evolving, with over 50 candidates in clinical development across hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) subtypes. Novel approaches—including antibody-drug conjugates (ADCs), immune checkpoint inhibitors, AKT inhibitors, PARP inhibitors, and TROP2-targeted therapies—are at the forefront of innovation as developers pursue more durable, biomarker-driven treatment strategies.

DelveInsight’s “HER2-Negative Metastatic Breast Cancer – Pipeline Insight, 2025” delivers an in-depth analysis of the dynamic therapeutic pipeline for HER2-negative MBC, which represents the majority of all breast cancer cases. HR+ is the most prevalent subtype, often treated with endocrine therapies, while TNBC remains a challenging, aggressive disease with fewer effective long-term options. Sacituzumab govitecan (Trodelvy), the first ADC approved for metastatic TNBC, is now being evaluated in HR+ settings, expanding its potential reach. Datopotamab deruxtecan, another TROP2-directed ADC, is progressing through Phase III trials in both HR+ and TNBC cohorts and is considered a next-generation competitor in the class.

Meanwhile, AstraZeneca’s capivasertib, an AKT inhibitor, has shown promise in HR+ MBC when combined with endocrine agents, as demonstrated in the pivotal CAPItello-291 trial. Immunotherapies like pembrolizumab (Keytruda) and atezolizumab continue to play a role in PD-L1+ TNBC, with ongoing evaluations in earlier-line settings and in combination with chemotherapy, ADCs, or targeted agents.

Biomarker-led approaches, including genomic profiling, circulating tumor DNA (ctDNA), and immune signatures, are shaping trial designs and patient stratification, especially as resistance to endocrine or chemotherapies emerges. Developers are also leveraging ADC platforms and bispecific antibodies to improve drug delivery specificity and reduce systemic toxicity, particularly in the TNBC population.

As 2025 progresses, the pipeline is shifting from traditional chemotherapy-based regimens toward personalized, mechanism-based therapies with higher efficacy and tolerability. Global trials are enrolling rapidly, aided by patient advocacy, expanded access initiatives, and regulatory mechanisms such as fast track, breakthrough designation, and accelerated approvals.

The future of HER2-negative MBC therapy lies in precision oncology and rational drug combinations, offering renewed hope for patients with both HR+ and TNBC subtypes. With more than 100 therapies in development and several late-stage candidates poised for regulatory milestones, this space is on the brink of a significant therapeutic transformation.

 

Interested in learning more about the current treatment landscape and the key drivers shaping the HER2 HER2-negative metastatic Breast Cancer pipeline? Click here

 

Key Takeaways from the HER2 Negative Metastatic Breast Cancer Pipeline Report

• DelveInsight’s HER2 Negative Metastatic Breast Cancer pipeline analysis depicts a strong space with 50+ active players working to develop 50+ pipeline drugs for HER2 Negative Metastatic Breast Cancer treatment.

• The leading HER2 Negative Metastatic Breast Cancer companies include BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others are evaluating their lead assets to improve the HER2 Negative Metastatic Breast Cancer treatment landscape.

• Key HER2 HER2-negative metastatic Breast Cancer pipeline therapies in various stages of development include Pamiparib, Onapristone, ASTX-727, Durvalumab, DAN-222, and others.

• In July 2025, Imagion Biosystems (ASX: IBX), a company focused on enhancing healthcare outcomes through early cancer detection using its proprietary MagSense HER2 imaging technology, announced an update for shareholders on its upcoming Phase 2 HER2 breast cancer clinical trial planned in the U.S.

• In June 2025, results from the Phase III OASIS-4 study showed that elinzanetant significantly reduced moderate to severe vasomotor symptoms (VMS) in women undergoing endocrine therapy for hormone receptor-positive (HR+) breast cancer. Statistically significant improvements were also seen in sleep disturbances, menopause-related quality of life, and VMS severity. The findings were presented at ASCO 2025 and published in the New England Journal of Medicine. OASIS-4 is the first global Phase III trial to evaluate elinzanetant for VMS linked to endocrine therapy in HR+ breast cancer.

• In April 2025, AstraZeneca and Daiichi Sankyo announced positive high-level results from the planned interim analysis of the DESTINY-Breast09 Phase III trial. The trial demonstrated that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab provided a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the current 1st-line standard of care regimen of taxane, trastuzumab, and pertuzumab (THP) for patients with HER2-positive metastatic breast cancer. This marks the first trial in over a decade to show superior efficacy across a broad HER2-positive metastatic patient population.

• In April 2025, AstraZeneca and Daiichi Sankyo’s ENHERTU (trastuzumab deruxtecan) was approved in the EU as monotherapy for adults with unresectable or metastatic HR-positive, HER2-low/ultralow breast cancer, after at least one endocrine therapy and when further endocrine therapy is unsuitable.

• In March 2025, the FDA granted orphan drug designation to NERLYNX (neratinib) for breast cancer patients with brain metastases. Neratinib is a tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive breast cancer after trastuzumab therapy.

• In January 2025, the FDA approved AstraZeneca’s DATROWAY (datopotamab deruxtecan or Dato-DXd) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously received endocrine therapy and chemotherapy.

 

Request a sample and discover the recent breakthroughs happening in the HER2-negative metastatic Breast Cancer pipeline landscape.

 

HER2 Negative Metastatic Breast Cancer Overview

HER2 Negative Metastatic Breast Cancer (MBC) is a subtype of breast cancer where the cancer cells lack overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This form of metastatic breast cancer tends to have different treatment options and prognosis compared to HER2-positive cases. Patients with HER2-negative MBC often rely on hormone therapies, chemotherapy, and emerging targeted treatments. The absence of HER2 makes therapies like trastuzumab ineffective, underscoring the need for alternative therapeutic strategies to manage disease progression and improve patient outcomes.

 

Find out more about HER2 Negative Metastatic Breast Cancer medication at https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-pipeline-insight

 

HER2 Negative Metastatic Breast Cancer Treatment Analysis: Drug Profile

Pamiparib: BeiGene

Pamiparib is a selective small-molecule inhibitor targeting PARP1 and PARP2 enzymes, under investigation as both a monotherapy and in combination treatments for various solid tumors. It stands out from other PARP inhibitors due to its ability to penetrate the brain, higher selectivity, strong DNA-trapping effects, and good oral bioavailability, as shown in preclinical studies. Pamiparib is currently in Phase II clinical trials for the treatment of HER2-negative metastatic breast cancer.

Onapristone: Context Therapeutics

ONA-XR, an extended-release form of onapristone, is an experimental drug that blocks progesterone signaling by preventing the progesterone receptor (PR) from binding to its partner. As the only known full PR antagonist, it targets PR-positive cancers—an area with no currently approved selective therapies. Preclinical and clinical evidence indicate that ONA-XR inhibits PR binding to chromatin, reduces cancer stem cell activity, and blocks immune evasion. It is presently being evaluated in multiple Phase II and Phase 0 trials for primary and metastatic breast, ovarian, and endometrial cancers, including HER2-negative metastatic breast cancer.

 

HER2 Negative Metastatic Breast Cancer Therapeutics Assessment

By Product Type

• Mono

• Combination

• Mono/Combination.

 

By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

By Route of Administration

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

 

By Molecule Type

• Oligonucleotide

• Peptide

• Small molecule

 

Scope of the HER2 Negative Metastatic Breast Cancer Pipeline Report

• Coverage: Global

• Key HER2 Negative Metastatic Breast Cancer Companies: BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others.

• Key HER2 Negative Metastatic Breast Cancer Pipeline Therapies: Pamiparib, Onapristone, ASTX-727, Durvalumab, DAN-222, and others.

 

Explore detailed insights on drugs used in the treatment of HER2-negative metastatic Breast Cancer here.

 

Table of Contents

1. Introduction

2. Executive Summary

3. HER2 Negative Metastatic Breast Cancer Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. HER2 Negative Metastatic Breast Cancer Pipeline Therapeutics

6. HER2 Negative Metastatic Breast Cancer Pipeline: Late-Stage Products (Phase III)

7. HER2 Negative Metastatic Breast Cancer Pipeline: Mid-Stage Products (Phase II)

8. HER2 Negative Metastatic Breast Cancer Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Metastatic Breast Cancer Pipeline Insight, 2025: Immunotherapy and ADCs Drive Innovation Across HR+ and TNBC Subtypes | DelveInsight

Central Retinal Vein Occlusion Pipeline Insight 2025: Emerging Therapies Targeting Vision Preservation and Vascular Recovery | DelveInsight

“Central Retinal Vein Occlusion Pipeline Insight”
The Central Retinal Vein Occlusion (CRVO) treatment landscape is advancing, with several companies developing novel therapies to improve outcomes. CRVO, caused by vein blockage in the retina, leads to vision loss, especially in older adults. While anti-VEGF remains standard, new approaches include sustained delivery, corticosteroid innovations, and therapies targeting retinal ischemia and vascular permeability.

DelveInsight’s “Central Retinal Vein Occlusion (CRVO) – Pipeline Insight, 2025” offers an in-depth analysis of the evolving CRVO pipeline, highlighting emerging therapeutics, ongoing clinical trials, regulatory progress, and key players shaping the market. The report captures the ongoing efforts to address unmet needs in managing chronic macular edema and reducing the treatment burden associated with frequent intravitreal injections.

Promising late-stage candidates include Kodiak Sciences’ KSI-301 (tarcocimab), a novel anti-VEGF antibody biopolymer conjugate with extended durability, and Roche’s Vabysmo (faricimab), a bispecific antibody targeting both Ang-2 and VEGF-A, already approved for other retinal vascular diseases and being evaluated in CRVO-specific trials. Additionally, companies such as Outlook Therapeutics, Oxurion, and Clearside Biomedical are pursuing differentiated strategies, including gene therapy, integrin inhibition, and suprachoroidal delivery of corticosteroids to enhance treatment outcomes.

Regulatory authorities are increasingly supporting innovative designs such as real-world data integration, patient-centric endpoints, and adaptive trial methodologies, especially as the need for long-acting therapies becomes more urgent. With the global burden of retinal vascular diseases rising, particularly due to aging populations and comorbidities like hypertension and diabetes, the CRVO treatment paradigm is poised for disruption.

As 2025 progresses, the CRVO pipeline reflects a shift from reactive symptom control to proactive, long-acting, and vision-preserving strategies. Backed by innovation, cross-sector collaboration, and expanding biomarker use, the field is rapidly advancing toward a more personalized and sustainable treatment era.

Interested in learning more about the current treatment landscape and the key drivers shaping the central retinal vein occlusion pipeline? Click here

 

Key Takeaways from the Central Retinal Vein Occlusion Pipeline Report

• DelveInsight’s central retinal vein occlusion pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for central retinal vein occlusion treatment.

• The leading central retinal vein occlusion companies include 3SBio, Gene Signal, Celon Pharma, The Emmes Company, LLC., and others are evaluating their lead assets to improve the central retinal vein occlusion treatment landscape.

• Key central retinal vein occlusion pipeline therapies in various stages of development include 610, GS-101 (Aganirsen), Ranibizumab biosimilar, Autologous Bone Marrow CD34+ Stem Cells, and others.

• In April 2025, Atsena Therapeutics announced that the FDA granted RMAT designation to ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS). ATSN-201 uses the company’s AAV.SPR spreading capsid to deliver therapeutic gene expression to central retinal photoreceptors without the need for foveal detachment surgery.

• In April 2025, Regeneron Pharmaceuticals announced that the FDA accepted for Priority Review its supplemental Biologics License Application for EYLEA HD® (aflibercept) Injection 8 mg. The application seeks approval for treating macular edema following retinal vein occlusion (RVO) and expanding the dosing schedule to monthly. The FDA’s target action date is August 19, 2025.

• In Dec 2024, Regeneron Pharmaceuticals announced that the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusions.

 

Central Retinal Vein Occlusion Overview

Central Retinal Vein Occlusion (CRVO) is a common retinal vascular disorder caused by a blockage in the central retinal vein, which leads to impaired blood drainage from the retina. This results in retinal swelling, hemorrhages, and reduced oxygen supply, ultimately causing vision loss. CRVO typically affects older adults and is often associated with risk factors such as hypertension, diabetes, glaucoma, and cardiovascular disease.

Symptoms include sudden, painless vision loss or blurred vision in one eye. Diagnosis is confirmed through clinical examination and imaging techniques like optical coherence tomography (OCT) and fluorescein angiography. Treatment aims to reduce retinal swelling and prevent complications, often involving intravitreal injections of anti-VEGF agents or corticosteroids. In severe cases, laser therapy may be used to manage neovascularization.

Find out more about central retinal vein occlusion medication at https://www.delveinsight.com/report-store/central-retinal-vein-occlusion-pipeline-insight

 

Central Retinal Vein Occlusion Treatment Analysis: Drug Profile

610: 3SBio

610 is a recombinant humanized IgG1 monoclonal antibody developed by 3SBio, designed to block interleukin-5 (IL-5) by binding to it, preventing its interaction with IL-5 receptors. This action helps inhibit the proliferation, differentiation, and activation of eosinophils. 610 is currently in Phase II clinical trials for the treatment of Central Retinal Vein Occlusion (CRVO).

GS-101 (Aganirsen): Gene Signal

GS-101 (aganirsen), developed by Gene Signal, is a topical antisense oligonucleotide therapy in eye drop form, aimed at treating corneal neovascularization—abnormal blood vessel growth in the cornea. It works by inhibiting the expression of IRS-1, a protein involved in new blood vessel formation. By blocking IRS-1, GS-101 helps prevent and reverse abnormal vascular growth, which can impair vision and lead to graft rejection.

Learn more about the novel and emerging central retinal vein occlusion pipeline therapies.

 

Central Retinal Vein Occlusion Therapeutics Assessment

By Product Type

• Mono

• Combination

• Mono/Combination.

 

By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

By Route of Administration

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

 

By Molecule Type

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

 

Scope of the Central Retinal Vein Occlusion Pipeline Report

• Coverage: Global

• Key Central Retinal Vein Occlusion Companies: 3SBio, Gene Signal, Celon Pharma, The Emmes Company, LLC., and others.

• Key Central Retinal Vein Occlusion Pipeline Therapies: 610, GS-101 (Aganirsen), Ranibizumab biosimilar, Autologous Bone Marrow CD34+ Stem Cells, and others.

Explore detailed insights on drugs used in the treatment of central retinal vein occlusion here.

 

Table of Contents

1. Introduction

2. Executive Summary

3. Central Retinal Vein Occlusion Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Central Retinal Vein Occlusion Pipeline Therapeutics

6. Central Retinal Vein Occlusion Pipeline: Late-Stage Products (Phase III)

7. Central Retinal Vein Occlusion Pipeline: Mid-Stage Products (Phase II)

8. Central Retinal Vein Occlusion Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Central Retinal Vein Occlusion Pipeline Insight 2025: Emerging Therapies Targeting Vision Preservation and Vascular Recovery | DelveInsight

Evolved Catering and Events Center Elevates Fallston’s Culinary and Event Experience

Evolved Catering and Events Center Elevates Fallston’s Culinary and Event Experience
Evolved Catering and Events Center continues to set the standard for hospitality in Harford County with a full range of services tailored for celebrations, corporate functions, and private gatherings. Known for delivering exceptional experiences with unmatched attention to detail, the company has become a premier destination for those seeking top-tier Fallston Catering Services.

Evolved Catering and Events Center offers more than just food—it provides a full-service approach to event planning. Whether for business conferences or social galas, the venue merges culinary artistry with personalized service, all within an elegant and adaptable setting. For those seeking a refined yet flexible Event Venue Fallston, the center offers a welcoming space equipped to host occasions of any scale.

The team behind Evolved Catering and Events Center brings together years of industry expertise, helping clients execute events that leave lasting impressions. From plated dinners to buffet spreads and cocktail-style receptions, the staff ensures every detail aligns with the vision of the event host. As a result, the venue has become a favored destination for Corporate Event Catering Fallston, offering professional-grade service designed to impress both clients and employees alike.

With a focus on quality, creativity, and consistency, Evolved Catering and Events Center remains a standout provider in Fallston’s growing events scene. Each event hosted within the venue reflects the team’s commitment to excellence and the community it serves.

Media Contact
Company Name: Evolved Catering and Events Center
Contact Person: Natalie Trabbold
Email: Send Email
Phone: (410) 776-8141
Address:2315 Belair Rd Unit B5
City: Fallston
State: MD
Country: United States
Website: https://evolvedeventscatering.com/

Jolly Results Launches Specialized Digital Marketing Services for HVAC, Plumbing, and Roofing Contractors Across the U.S.

Jolly Results, a newly launched digital marketing agency, is making waves in the home services industry with its exclusive focus on HVAC, plumbing, and roofing contractors across the United States. After more than eight years of behind-the-scenes experience working as SEO specialists for established marketing agencies, the team at Jolly Results is stepping out on its own with a promise: to deliver fast, effective, and lead-driven marketing solutions tailored to the needs of home service professionals.

Built from the ground up to understand the unique challenges of local contractors, Jolly Results offers a complete digital growth package that includes professional website design, Local SEO, and Google & Local Services Ads (LSA) and has been designed to generate consistent leads and help contractors dominate their local markets.

“We’re not here to offer generic websites or cookie-cutter campaigns,” a company spokesperson said. “Everything we create is built for speed, performance, and the specific needs of HVAC techs, roofers, and plumbers who rely on leads to keep their business running.”

Through a simplified four-step process: audit, launch, generate, and scale, Jolly Results brings results in record time. Websites go live within seven days, ads start generating leads within 24 to 48 hours, and Local SEO campaigns begin showing results within the first 30 to 60 days.

Real contractors are already seeing the difference. In Phoenix, an HVAC company reported a 340% increase in leads and tripled their revenue within eight months. A Dallas roofing contractor generated $2.8 million in new business from storm-related Google Ads campaigns. And in Denver, a plumbing contractor now ranks #1 for high-intent local search terms like “emergency plumber near me,” thanks to Jolly Results’ Local SEO strategy.

Jolly Results offers customized solutions for each trade. HVAC websites highlight emergency contact features and seasonal services. Plumbing campaigns focus on emergency repairs, water heater installations, and trust-building content. Roofing strategies are optimized around storm damage, insurance claims, and urgent roof repairs. Each campaign is carefully designed to address the real-time needs and search behaviors of homeowners in the contractor’s local area.

More than just another marketing agency, Jolly Results is positioning itself as a long-term partner to contractors who are serious about scaling. Its service packages are priced transparently, with websites starting at $1,497, Local SEO at $997/month, and Google/LSA Ads at $1,497/month, and include full strategy, implementation, and ongoing optimization.

“Our mission is simple,” said the company’s spokesperson. “We help home service businesses generate more leads, close more jobs, and grow their revenue faster, without the runaround.”

Contractors interested in working with Jolly Results can start with a free marketing audit and consultation to assess their current online presence and get a tailored strategy for local market domination.

About Jolly Results

Jolly Results is a U.S.-based digital marketing agency built exclusively for HVAC, plumbing, and roofing contractors. With years of experience and deep industry specialization, Jolly Results helps home service businesses grow their lead flow, improve their visibility, and increase revenue through data-driven websites, SEO, and Google Ads campaigns.

To learn more, visit www.jollyresults.com.

For the latest updates, follow Jolly Results on social media:

Facebook: https://www.facebook.com/jollyresults

LinkedIn: https://www.linkedin.com/company/jolly-results/

Instagram: https://www.instagram.com/jollyresults/

YouTube: https://www.youtube.com/@JollyResults

X @JollyResults

Media Contact
Company Name: Jolly Results
Contact Person: Sarah
Email: Send Email
Country: United States
Website: www.jollyresults.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jolly Results Launches Specialized Digital Marketing Services for HVAC, Plumbing, and Roofing Contractors Across the U.S.